Unprofitable companies face headwinds as they struggle to control operating costs. Some may invest heavily, but the majority fail to translate spending into sustainable growth.
A lack of profit can lead to problems, but StockStory will help you identify the companies that have a chance to survive. With that in mind, here are three unprofitable companies that won’t make it, and some better opportunities instead.
GAAP operating margin over 12 months: -2.2%
Founded in 1895, Albany (NYSE:AIN) is a global textile and materials processing company specializing in machine clothing for paper mills and composite structures for the aerospace and other industries.
Why do we avoid AIN?
-
Annual sales growth of 1.5% over the past two years was slower than in the industrial sector
-
The 10.7 percentage point decline in free cash flow margin over the past five years reflects the company’s increased investments to defend its market position
-
Diminishing returns on capital from an already weak starting point show that management’s past investment decisions and current situation are ineffective
Albany trades at $57.90 per share, or 23.7x forward price-to-earnings ratio. Read our free research report and find out why you should think twice about including AIN in your portfolio: it’s free.
GAAP operating margin over 12 months: -1.141%
Strategy (NASDAQ:MSTR), once a traditional business intelligence software provider, is developing AI-powered business analytics software while functioning as a major corporate holder of Bitcoin cryptocurrency.
Why is MSTR risky?
-
MicroStrategy’s core analytics software is overshadowed by its all-in Bitcoin strategy, leaving product innovation and business deals hungry for attention
-
The Company’s Debt-Financed Bitcoin Purchases Tie Shareholder Fortunes to Crypto Fluctuations and Interest Rates, Increasing Downside Risk and Uncertainty
-
On the plus side, the massive Bitcoin treasury gives executive chairman Michael Saylor a unique springboard to capture crypto upside and court investors looking for exposure to digital assets.
Strategy is trading at $134.85 per share at a forward price-to-sales of 76.4x. To learn more about why MSTR doesn’t meet our standards, check out our free in-depth research report.
GAAP operating margin over 12 months: -8.7%
With a diverse portfolio of eight FDA-approved medications targeting neurological disorders, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system disorders, including epilepsy, ADHD, Parkinson’s disease and migraines.
Why are we careful with SUPN?
-
Annual revenue growth of 5.6% over the past five years was below our healthcare industry standards
-
Its $717.2 million revenue base puts the company at a disadvantage against larger competitors that exhibit economies of scale
-
Free cash flow margin fell 14.4 percentage points over the past five years, implying the company became more capital intensive as competition increased
Supernus Pharmaceuticals’ share price of $49.90 implies a valuation ratio of 21.5x forward price-to-earnings ratio. If you’re considering SUPN for your portfolio, check out our FREE research report to learn more.
ONE MORE THING: Top 6 stocks for this week. This market quickly separates quality stocks from expensive stocks. AI is taking down entire industries without warning. With such a rapid rotation, you need more than a list of good companies.
Our AI system flagged Palantir before it hit 1,662%. AppLovin before it was running 753%. Nvidia before it turned 1.178%. Every week it produces 6 new names that pass the same tests. Receive our top 6 stocks for free HERE.
The stocks that made our list in 2020 include now household names like Nvidia (+1.326% between June 2020 and June 2025) and under-the-radar companies like the once microcap company Tecnoglass (+1.754% over five years). Find your next big winner today with StockStory.
